Long-term Evaluation of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Biological Disease-modifying Antirheumatic Drugs.

Yoshiya Tanaka,Tsutomu Takeuchi,Hisashi Yamanaka,Toshihiro Nanki,Hisanori Umehara,Nobuyuki Yasuda,Fumitoshi Tago,Yasumi Kitahara,Makoto Kawakubo,Kentaro Torii,Seiichiro Hojo,Tetsu Kawano,Toshio Imai

Modern rheumatology（2023）

引用 2|浏览13

暂无评分

摘要

E6011 was well tolerated in active RA patients who had shown an inadequate response to biologic DMARDs, but no clear benefit in the ACR20 response rates was observed. Further studies are needed to clarify the clinical benefit of E6011.

查看译文

关键词

E6011,fractalkine,long-term,monoclonal antibody,rheumatoid arthritis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要